McNeal Karleen M, Meyer Renee P, Lukacs Karen, Senseney Anna, Mintzer Jacob
Alzheimer's Research and Clinical Programs, VA Medical Center and Medical University of South Carolina, Geriatrics and Extended Care, Charleston, SC, 29406-6076, USA.
Expert Opin Pharmacother. 2008 Oct;9(14):2537-43. doi: 10.1517/14656566.9.14.2537.
Alzheimer's dementia (AD) occurs in 6 - 8% of persons older than 65 years. The prevalence increases to 30% among those 85 years or older. Among AD patients, the incidence of psychosis is 30 - 50%. Safe and appropriate use of psychotropic agents is a relevant clinical concern for this population.
This review addresses risks and potential benefits when risperidone is used for treating AD-associated psychosis.
Through literature review and clinical experience, the authors discuss the clinical efficacy, safety, and regulatory issues concerning risperidone treatment for this group of patients.
Despite concerns about safety, risperidone remains a popular therapeutic choice for AD patients with psychosis. Subsets of these patients with more severe agitation and aggression may experience greater behavioral benefit.
65岁以上人群中，阿尔茨海默病性痴呆（AD）的发病率为6%-8%。85岁及以上人群中，患病率增至30%。在AD患者中，精神病的发病率为30%-50%。安全、恰当地使用精神药物是该人群的一个相关临床关注点。
本综述探讨利培酮用于治疗AD相关性精神病时的风险和潜在益处。
通过文献综述和临床经验，作者讨论了利培酮治疗该组患者的临床疗效、安全性和监管问题。
尽管存在安全性担忧，但利培酮仍是患有精神病的AD患者常用的治疗选择。这些患者中，有更严重激越和攻击行为的亚组可能会在行为方面获得更大益处。
